Smarter drugs: A focus on pan-specific monoclonal antibodies

BioDrugs

Volumn 25, Issue 6, 2011, Pages 357-364

  Fagète, Séverine ^a   Fischer, Nicolas ^a  

^a NOVIMMUNE SA   (Switzerland)

Author keywords

Biotechnology; Monoclonal antibodies; Recombinant proteins; Research and development

Indexed keywords

BOTULINUM TOXIN A; CXCL9 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TRASTUZUMAB; VASCULOTROPIN;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BINDING AFFINITY; BINDING KINETICS; CANCER THERAPY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; CROSS REACTIONS; HUMANS;

EID: 80555156163     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11594690-000000000-00000     Document Type: Review

References (36)

1. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011 Jan 11; 3 (1): 77-99
2. Caravella J, Lugovskoy A. Design of next-generation protein therapeutics. Curr Opin Chem Biol 2010 Aug; 14 (4): 520-8
3. Cuesta AM, Sainz-Pastor N, Bonet J, et al. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 2010 Jul; 28 (7): 355-62
4. Eren R, Landstein D, Terkieltaub D, et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006 Mar; 80 (6): 2654-64
5. Larbouret C, Robert B, Navarro-Teulon I, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007 Jun 1; 13 (11): 3356-62
6. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004 Apr 1; 64 (7): 2343-6
7. Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkins lymphoma. J Clin Oncol 2006 Aug 20; 24 (24): 3880-6
8. Goudsmit J, Marissen WE, Weldon WC, et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006 Mar 15; 193 (6): 796-801
9. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl JMed 2010 Jan 21; 362 (3): 197-205
10. U.S.Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation andResearch. Guidance for industry codevelopment of two or more unmarketed investigational drugs for use in combination, 2010 Dec [online]. Available from URL: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf [Accessed 2011 Sep 15]
11. Ishida I, TomizukaK, Yoshida H, et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002; 4 (1): 91-102
12. Bregenholt S, Jensen A, Lantto J, et al. Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr Pharm Des 2006; 12 (16): 2007-15
13. Wiberg FC, Rasmussen SK, Frandsen TP, et al. Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng 2006 Jun 5; 94 (2): 396-405
14. Kufer P, Lutterbuse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 2004 May; 22 (5): 238-44
15. Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs 2010; 24 (2): 89-98
16. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009 Jun 15; 69 (12): 4941-4
17. Wolf E, Hofmeister R, Kufer P, et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005 Sep 15; 10 (18): 1237-44
18. Lum LG, Thakur A. Targeting T cells with bispecific antibodies for cancer therapy. Biodrugs 2011; 25 (6): 365-79
19. Fischer N, Leger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74 (1): 3-14
20. NovImmune. Kappa-Lambda bodies [online]. Available from URL: http://www.novimmune.com/technology/our-technologies.html [Accessed 2011 Sep 21]
21. Merus. Applying MeMO™ and Oligoclonics™ technologies for bispecific antibody generation [online]. Available from URL: http://www.merus.nl/technology/bispecifics.html [Accessed 2011 Sep 21
22. Garcia-RodriguezC, Levy R, Arndt JW, et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007 Jan; 25 (1): 107-16
23. Boulanger MJ, Bankovich AJ, Kortemme T, et al. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell 2003 Sep; 12 (3): 577-89
24. Fagete S, Ravn U, GueneauF, et al. Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent.MAbs 2009 May; 1 (3): 288-96
25. Bostrom J,Yu SF, KanD, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009 Mar 20; 323 (5921): 1610-4
26. Garcia-Rodriguez C, Geren IN, Lou J, et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel 2011 Mar; 24 (3): 321-31
27. Reid C, Rushe M, Jarpe M, et al. Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody. Protein Eng Des Sel 2006 Jul; 19 (7): 317-24
28. Mariuzza RA. Multiple paths to multispecificity. Immunity 2006 Apr; 24 (4): 359-61
29. Erijman A, Aizner Y, Shifman JM. Multispecific recognition: mechanism, evolution, and design. Biochemistry 2011 Feb 8; 50 (5): 602-11
30. James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity. Science 2003 Feb 28; 299 (5611): 1362-7
31. Bostrom J, Haber L, Koenig P, et al. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One 2011; 6 (4): e17887
32. Arevalo JH, Taussig MJ,Wilson IA. Molecular basis of crossreactivity and the limits of antibody-antigen complementarity. Nature 1993 Oct 28; 365 (6449): 859-63
33. Fuh G, Haber L, Schaefer G, et al., inventors. Genentech, Inc., assignee. Anti- HER antibodies. US patent 0255010 A1. 2010 Oct 7
34. Genentech. A study of the safety and pharmacokinetics of MEHD7945A in patients with locally advanced or metastatic epithelial tumors. [Clinical- Trials.gov identifier NCT01207323]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www.clinicaltrials. gov[Accessed 2011 Oct 1]
35. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010 Mar 16; 2 (2): 129-36
36. Strohlein MA, Heiss MM. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. Future Oncol 2010 Sep; 6 (9): 1387-94